Download our whitepaper,

"Advancing Lung Cancer Clinical Trials: Diagnosis, Epidemiology, and Pivotal Endpoints"

iNGENu CRO - Lung Cancer Clinical Trials

What's Inside:

  • Key FDA-Approved Pivotal Endpoints for Lung Cancer Clinical Trials.
  • Optimizing Recruitment with Adaptive Trial Designs for Lung Cancer.
  • Comprehensive Analysis of FDA-Approved Lung Cancer Drugs.
  • How Diagnostic Criteria for Lung Cancer Have Evolved and Impact Research.
  • Overcoming Common Pitfalls in Lung Cancer Clinical Trials.
  • And additional insights to drive your trial's success.

Access your complimentary whitepaper today:

Lung Cancer

Lung cancer is a serious and often aggressive form of cancer that originates in the lungs.

It is typically characterized by symptoms such as a persistent cough, chest pain, hemoptysis (coughing up blood), and dyspnea (shortness of breath). The disease can progress rapidly, with many patients experiencing advanced stages at the time of diagnosis. The disease demands long-term management and significantly impacts quality of life.

Research in lung cancer has evolved from viewing it as a localized disease to understanding its complex biology, including genetic mutations, tumor microenvironment, and molecular pathways.

This growing knowledge has been pivotal in developing modern therapeutic approaches, such as targeted therapies, immunotherapy, and personalized medicine, which aim to manage symptoms, slow disease progression, and improve the overall survival and quality of life for patients.

iNGENū’s team of researchers and clinicians is dedicated to advancing Lung Cancer research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by lung cancer.

 

30%

of lung cancer cases occur in people who have never smoked

 

Early-stage lung cancer can often be treated with surgery, with a survival rate of 

60%

 

57%

of Lung Cancer cases are diagnosed at an advanced stage



 



Our clinical team has over

120

years of combined clinical trial experience